Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients

Part of paid clinical trials in Miami, Florida.

Sponsor
University of Miami
Study ID
NCT06494033
Status
Recruiting
Apply to this trial

Conditions

  • Lung Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.

Key Dates

Start date
Jul 3, 2024
Status verified
Mar 2026
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Prophylaxis guided by Cytomegalovirus-specific T cell Immunity
    The immunological response of participants in this group will be followed for 1 year.

Primary Outcome Measure

Positive CMV Immunoglobulin (IgG) positive lung transplant [ Time Frame: Up to 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MiamiMiamiFlorida33136
Yoichiro Natori, MD
[email protected]
3053556323
Lissett Moni
[email protected]
3053555418
Yoichiro Natori, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Miami, FL

By research site
University of Miami· Miami, FL

Related Studies